New drug IPG1094 gets first human test in china
NCT ID NCT07679113
First seen Jul 01, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This phase 1 trial tests the drug IPG1094 in 24 healthy Chinese adults to understand how the body absorbs, processes, and eliminates it. Part A examines whether food affects a single dose, while Part B looks at repeated dosing over 10 days. All participants are monitored for safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- IPG1094
- What this could lead to
- If successful, this study will provide key data on how IPG1094 behaves in the body, supporting future trials for potential therapeutic uses.
- What could go wrong
- This is an early phase 1 trial in only 24 healthy volunteers, so results may not predict effects in patients. The drug may cause side effects or fail in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male and female healthy Chinese participants aged 18 to 50 years (inclusive). 2. Comprehensive assessments including physical examination, vital signs, 12-lead ECG, chest X-ray and laboratory tests are normal or with abnormalities judged not clinically significant by the investigator. 3. Body weight: Male ≥50.0 kg, Female ≥45.0 kg; Body Mass Index (BMI) ranges from 19.0 to 26.0 (inclusive). BMI = Weight(kg) / Height(m)². 4. Female participants are non-pregnant and non-lactating. 5. Participants have no pregnancy plan and no sperm/egg donation plan from 2 weeks before screening to 6 months after the end of the study, and agree to use effective contraception during this period. 6. Voluntarily sign the written informed consent form, and fully understand the trial content and potential adverse reactions. Exclusion Criteria: 1. History of severe cardiovascular, respiratory, hepatic, renal, gastrointestinal, neurological, psychiatric or other systemic diseases with clinical significance. 2. QTcF interval \>450 ms (male) or \>470 ms (female). 3. History of recurrent headache, nausea or vomiting. 4. Blood loss ≥400 mL within 3 months before screening, or plan to donate blood during the study. 5. History of orthostatic hypotension or dysphagia. 6. History of gastrointestinal diseases affecting drug absorption. 7. Lactose intolerance, special dietary restrictions, or unable to follow unified diet requirements during the trial. 8. History of drug/food allergy, drug abuse or alcohol abuse. 9. Heavy smoking, excessive intake of tea, coffee or caffeinated beverages within 3 months before screening. 10. Use of any prescription drugs, over-the-counter drugs, health products or Chinese herbal medicines within 14 days before screening. 11. Use of drugs affecting liver metabolism or gastrointestinal environment within 30 days before screening. 12. Intake of citrus fruits/juices within 5 days before screening or during the trial. 13. Participated in other clinical trials within 3 months before screening. 14. Positive result of urine drug screen or breath alcohol test at admission. 15. Difficulty in venous blood collection, history of syncope during blood collection. 16. Acute illness before screening, or other conditions judged inappropriate for participation by the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shanghai Xuhui Central Hospital
RECRUITINGShanghai, Xuhui, 200031, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe the nerve highways behind strength gains
- New syphilis test kits put to the test with donated blood
- Can a copy of a blockbuster arthritis drug match the original? scientists test it in healthy people
- Novo nordisk tests Brand-New molecule in humans for the first time
- New sedative candidate goes Head-to-Head with propofol in early human test
- Can a Room-Temperature dairy drink build muscle?